A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 170 participants.
Also called NCT07668336
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 170 participants
- Sponsor
- Registry
-
NCT07668336 -
2025-524811-35-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Brazil, India, Italy, Japan, Mexico, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07668336. Randomized; no masking; primary purpose treatment. Start 2026-07-08 (actual); primary completion 2030-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- Acronym
- ACHIEVE-PEDS
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07668336- Content hash
dccb2c56f320e109c7dede46ac05716d1e7ea0f7c3e8066d7190290a3df47c5b